BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 23085463)

  • 1. Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study.
    Wolschke C; Stübig T; Hegenbart U; Schönland S; Heinzelmann M; Hildebrandt Y; Ayuk F; Atanackovic D; Dreger P; Zander A; Kröger N
    Exp Hematol; 2013 Feb; 41(2):134-142.e3. PubMed ID: 23085463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial.
    Kneppers E; van der Holt B; Kersten MJ; Zweegman S; Meijer E; Huls G; Cornelissen JJ; Janssen JJ; Huisman C; Cornelisse PB; Bruijnen CP; Emmelot M; Sonneveld P; Lokhorst HM; Mutis T; Minnema MC
    Blood; 2011 Sep; 118(9):2413-9. PubMed ID: 21690556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.
    Atanackovic D; Cao Y; Luetkens T; Panse J; Faltz C; Arfsten J; Bartels K; Wolschke C; Eiermann T; Zander AR; Fehse B; Bokemeyer C; Kroger N
    Haematologica; 2008 Mar; 93(3):423-30. PubMed ID: 18287134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells.
    Minnema MC; van der Veer MS; Aarts T; Emmelot M; Mutis T; Lokhorst HM
    Leukemia; 2009 Mar; 23(3):605-7. PubMed ID: 18784738
    [No Abstract]   [Full Text] [Related]  

  • 6. Spontaneous autologous graft-versus-host disease in plasma cell myeloma autograft recipients: flow cytometric analysis of hematopoietic progenitor cell grafts.
    Lazarus HM; Sommers SR; Arfons LM; Fu P; Ataergin SA; Kaye NM; Liu F; Kindwall-Keller TL; Cooper BW; Laughlin MJ; Creger RJ; Barr PM; Gerson SL; Kaplan D
    Biol Blood Marrow Transplant; 2011 Jul; 17(7):970-8. PubMed ID: 21440080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of early NK cell recovery on development of GvHD and CMV reactivation in dose-reduced regimen prior to allogeneic PBSCT.
    Scholl S; Mügge LO; Issa MC; Kasper C; Pachmann K; Höffken K; Sayer HG
    Bone Marrow Transplant; 2005 Jan; 35(2):183-90. PubMed ID: 15531897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenalidomide plus donor-lymphocytes infusion after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with high-risk multiple myeloma.
    El-Cheikh J; Crocchiolo R; Furst S; Ladaique P; Castagna L; Faucher C; Granata A; Oudin C; Lemarie C; Calmels B; Stoppa AM; Schiano De Colella JM; Duran S; Chabannon C; Blaise D
    Exp Hematol; 2012 Jul; 40(7):521-7. PubMed ID: 22446605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunological and clinical effects of post-transplant G-CSF versus placebo in T-cell replete allogeneic blood transplant patients: results from a randomized double-blind study.
    Joshi SS; Bishop MR; Lynch JC; Tarantolo SR; Abhyankar S; Bierman PJ; Vose JM; Geller RB; McGuirk J; Foran J; Bociek RG; Hadi A; Day SD; Armitage JO; Kessinger A; Pavletic ZS
    Cytotherapy; 2003; 5(6):542-52. PubMed ID: 14660050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells.
    Lioznov M; El-Cheikh J; Hoffmann F; Hildebrandt Y; Ayuk F; Wolschke C; Atanackovic D; Schilling G; Badbaran A; Bacher U; Fehse B; Zander AR; Blaise D; Mohty M; Kröger N
    Bone Marrow Transplant; 2010 Feb; 45(2):349-53. PubMed ID: 19584825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients.
    Kröger N; Zabelina T; Klyuchnikov E; Kropff M; Pflüger KH; Burchert A; Stübig T; Wolschke C; Ayuk F; Hildebrandt Y; Bacher U; Badbaran A; Schilling G; Hansen T; Atanackovic D; Zander AR
    Bone Marrow Transplant; 2013 Mar; 48(3):403-7. PubMed ID: 22863722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lenalidomide consolidation and maintenance therapy after autologous stem cell transplant for multiple myeloma induces persistent changes in T-cell homeostasis.
    Clave E; Douay C; Coman T; Busson M; Bompoint C; Moins-Teisserenc H; Glauzy S; Carmagnat M; Gorin NC; Toubert A; Garderet L
    Leuk Lymphoma; 2014 Aug; 55(8):1788-95. PubMed ID: 24237448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
    Dimopoulos M; Spencer A; Attal M; Prince HM; Harousseau JL; Dmoszynska A; San Miguel J; Hellmann A; Facon T; Foà R; Corso A; Masliak Z; Olesnyckyj M; Yu Z; Patin J; Zeldis JB; Knight RD;
    N Engl J Med; 2007 Nov; 357(21):2123-32. PubMed ID: 18032762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD4+CD25+ regulatory T cell depletion improves the graft-versus-tumor effect of donor lymphocytes after allogeneic hematopoietic stem cell transplantation.
    Maury S; Lemoine FM; Hicheri Y; Rosenzwajg M; Badoual C; Cheraï M; Beaumont JL; Azar N; Dhedin N; Sirvent A; Buzyn A; Rubio MT; Vigouroux S; Montagne O; Bories D; Roudot-Thoraval F; Vernant JP; Cordonnier C; Klatzmann D; Cohen JL
    Sci Transl Med; 2010 Jul; 2(41):41ra52. PubMed ID: 20650872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.
    Attal M; Lauwers-Cances V; Marit G; Caillot D; Moreau P; Facon T; Stoppa AM; Hulin C; Benboubker L; Garderet L; Decaux O; Leyvraz S; Vekemans MC; Voillat L; Michallet M; Pegourie B; Dumontet C; Roussel M; Leleu X; Mathiot C; Payen C; Avet-Loiseau H; Harousseau JL;
    N Engl J Med; 2012 May; 366(19):1782-91. PubMed ID: 22571202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD8+ T cell dose affects development of acute graft-vs-host disease following reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
    Mohty M; Bagattini S; Chabannon C; Faucher C; Bardou VJ; Bilger K; Vey N; Gaugler B; Stoppa AM; Coso D; Ladaique P; Olive D; Viens P; Blaise D
    Exp Hematol; 2004 Nov; 32(11):1097-102. PubMed ID: 15539088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lenalidomide in the treatment of multiple myeloma: a review.
    Armoiry X; Aulagner G; Facon T
    J Clin Pharm Ther; 2008 Jun; 33(3):219-26. PubMed ID: 18452408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-CD34+ cells, especially CD8+ cytotoxic T cells and CD56+ natural killer cells, rather than CD34 cells, predict early engraftment and better transplantation outcomes in patients with hematologic malignancies after allogeneic peripheral stem cell transplantation.
    Kim DH; Won DI; Lee NY; Sohn SK; Suh JS; Lee KB
    Biol Blood Marrow Transplant; 2006 Jul; 12(7):719-28. PubMed ID: 16785061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).
    Dawar R; Hernandez-Ilizaliturri F
    Best Pract Res Clin Haematol; 2012 Jun; 25(2):185-90. PubMed ID: 22687454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning.
    Ogawa H; Ikegame K; Yoshihara S; Kawakami M; Fujioka T; Masuda T; Taniguchi Y; Hasei H; Kaida K; Inoue T; Kim EH; Kawase I
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1073-84. PubMed ID: 17084371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.